STOCK TITAN

Sensei Biotherapeutics, Inc. Stock Price, News & Analysis

SNSE Nasdaq

Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.

Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biotechnology pioneer developing tumor microenvironment-activated immunotherapies. This page aggregates all material news and regulatory disclosures about the company's innovative TMAb™ platform and clinical programs.

Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, financial disclosures, and scientific developments. Our curated collection ensures efficient tracking of key milestones in Sensei's quest to create conditionally active cancer therapies.

The repository includes earnings reports, FDA communications, research collaborations, and peer-reviewed publication highlights. All content is vetted for relevance to SNSE's core focus on overcoming immune suppression in solid tumors through pH-sensitive antibody engineering.

Bookmark this page for structured access to Sensei's evolving pipeline updates and corporate announcements. Regularly refreshed content supports informed decision-making about this innovative player in next-generation immuno-oncology.

Rhea-AI Summary

EGLE Therapeutics announced the appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. Dr. Motlagh's expertise will drive clinical strategy and development, focusing on advancing the company's pipeline in oncology and auto-immunity. Mr. Celebi brings over 25 years of experience in building biotechnology companies. His extensive background includes serving as President and CEO of Sensei Biotherapeutics (NASDAQ: SNSE) and holding leadership positions in various biotech firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
management
-
Rhea-AI Summary

Sensei Biotherapeutics, Inc. reported financial results for Q1 2024 and recent business highlights, including clinical trial progress, upcoming data presentations, and a strong balance sheet with cash runway into Q4 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
none

FAQ

What is the current stock price of Sensei Biotherapeutics (SNSE)?

The current stock price of Sensei Biotherapeutics (SNSE) is $9.53 as of October 28, 2025.

What is the market cap of Sensei Biotherapeutics (SNSE)?

The market cap of Sensei Biotherapeutics (SNSE) is approximately 12.8M.
Sensei Biotherapeutics, Inc.

Nasdaq:SNSE

SNSE Rankings

SNSE Stock Data

12.76M
830.72k
34.14%
5.58%
0.82%
Biotechnology
Pharmaceutical Preparations
Link
United States
ROCKVILLE